Biocad sees arthritis drug BCD-121 as potential game-changer

11 July 2016

Early data suggests that leading Russian biotech firm Biocad could have a new rheumatoid arthritis (RA) drug which increases the efficacy of treatment by up to 20%.

Biocad has invested more than 155 million roubles ($2.4 million) in the very early development stages of BCD-121, which has a mechanism of action unlike existing treatments.

Medicines which are currently available for RA are able to inhibit one inflammatory protein or its receptor, for example tumor necrosis factor or interleukin 17 or receptor of interleukin 6.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK